Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Peptic Ulcer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    25 result(s) found for: Peptic Ulcer. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2006-005454-76 Sponsor Protocol Number: GAS-04-04 Start Date*: 2004-10-01
    Sponsor Name:IRCCS CASA SOLLIEVO DELLA SOFFERENZA
    Full Title: PPI as an adjunct to endoscopic hemostasis for bleeding peptic ulcer a randomized clinical trial of a high vs a standard regimen for the i.v. drug infusion
    Medical condition: Patients with peptic ulcer bleeding
    Disease: Version SOC Term Classification Code Term Level
    8.1 10034344 Peptic ulcer haemorrhage LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-005073-22 Sponsor Protocol Number: D961FC00003 Start Date*: 2007-01-23
    Sponsor Name:AstraZeneca AB
    Full Title: A randomized, double-blind, parallel-group study to assess the effect of esomeprazole 20 and 40 mg od versus placebo on the occurrence of peptic ulcers during 26 weeks in patients on continous low-...
    Medical condition: Target subject population are male and female subjects requiring low-dose acetylsalicylic acid (75-325 mg daily) who are Helicobacter pylori negative and who are at increased risk of developing ga...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10017886 Gastroduodenal ulcer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) PT (Completed) CZ (Completed) DE (Completed) SK (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2018-000213-20 Sponsor Protocol Number: D961WC00001 Start Date*: 2023-06-06
    Sponsor Name:Astrazeneca K.K.
    Full Title: An Open Label, Parallel Group, Multi-centre, Phase III Study to Assess the Efficacy and Safety of D961H for the Maintenance Therapy Following Initial Treatment in Japanese Paediatric Patients with ...
    Medical condition: Reflux esophagitis in Japanese paediatric patients Past gastric ulcer or duodenal ulcer in Japanese paediatric patients
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10038262 Reflux esophagitis LLT
    21.1 100000004865 10036904 Prophylaxis of NSAID gastric ulceration LLT
    20.0 100000004856 10013858 Duodenal ulcer, unspecified as acute or chronic, without mention of haemorrhage or perforation LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-003425-96 Sponsor Protocol Number: 11091 Start Date*: 2011-12-15
    Sponsor Name:University of Nottingham
    Full Title: Helicobacter eradication to prevent ulcer bleeding in aspirin users: a large simple randomised controlled trial
    Medical condition: Helicobacter eradication to prevent ulcer bleeding in aspirin users
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2005-002441-39 Sponsor Protocol Number: D961DC00001 Start Date*: 2005-11-07
    Sponsor Name:AstraZeneca AB
    Full Title: A randomised, double-blind, parallel-group, placebo controlled study of esomeprazole i.v. (bolus infusion of 80 mg followed by a continuous infusion of 8 mg per hour) administered for 72 hours to a...
    Medical condition: Gatrointestinal haemorrhages NEC. (Bleeding gastric or duodenal ulcer will be investigated). MedDRA classification code Level: HLGT = High Level Group Term. See below.
    Disease: Version SOC Term Classification Code Term Level
    8.0 10017959 HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FI (Completed) SE (Completed) NO (Completed) DK (Completed) ES (Completed) AT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-005174-23 Sponsor Protocol Number: CAVA2Dec04 Start Date*: 2005-04-11
    Sponsor Name:NHS Grampian
    Full Title: Is smooth muscle mitogenesis down regulated by platelet inactivation with combination antiplatelet therapy after angioplasty for claudication?
    Medical condition: Intermittent claudication = stenosis of superficial femoral artery requiring percutaneous angioplasty
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-011978-15 Sponsor Protocol Number: 252/09 Start Date*: 2010-02-22
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: Effectiveness of acetylcysteine in first line therapy to cure Helicobacter pylori. Pilot study.
    Medical condition: peptic, duodenal and gastric ulcer with Helicobacter pylori infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10051790 LLT
    9.1 10065231 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002668-28 Sponsor Protocol Number: HP-301 Start Date*: 2020-04-21
    Sponsor Name:Phathom Pharmaceuticals, Inc.
    Full Title: A Phase 3 Randomized Multicenter Study to Evaluate the Efficacy and Safety of Open-Label Dual Therapy with Oral Vonoprazan 20 mg or Double-Blind Triple Therapy with Oral Vonoprazan 20 mg Compared t...
    Medical condition: Helicobacter pylori infection
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004862 10019377 Helicobacter pylori infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) GB (GB - no longer in EU/EEA) CZ (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2010-019064-36 Sponsor Protocol Number: MA-PY-Hp09-01 Start Date*: 2011-07-17
    Sponsor Name:Axcan Pharma INC
    Full Title: Eficacia y seguridad de PYLERA (subcitrato potásico de bismuto, metronidazol y clorhidrato de tetraciclina) con omeprazol, administrados 10 días en sujetos con fracaso del tratamiento de erradicaci...
    Medical condition: erradicación de Helicobacter pylori
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10019377 Helicobacter pylori infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-002738-55 Sponsor Protocol Number: 69HCL16-0134 Start Date*: 2017-01-06
    Sponsor Name:Hospices Civils de Lyon
    Full Title: Safety of Intraperitoneal (IP) OXAliplatin (OXA) in Association With Systemic FOLFIRI Bevacizumab Chemotherapy in Patients With Peritoneal Carcinosis ( IPOXA )
    Medical condition: Patients with peritoneal carcinosis of colorectal origin and uncertain resectability with an indication for systemic chemotherapy compatible with the FOLFIRI + bevacizumab combination.
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10052171 Peritoneal carcinoma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-005055-23 Sponsor Protocol Number: ENDO-002/08 Start Date*: 2009-03-05
    Sponsor Name:OSPEDALE MAGGIORE DI MILANO (IRCCS)
    Full Title: TREATMENT OF HYPERPARATHYROIDISM IN PATIENTS WITH MULTIPLE ENDOCRINE NEOPLASIA TYPE 1 (MEN1) WITH THE CALCIMIMETIC AGENT CINACALCET
    Medical condition: Primary hyperparathyroidism in patients affected with multiple endocrine neoplasia syndrome type 1 (MEN1)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027180 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-001877-13 Sponsor Protocol Number: TMT107235 Start Date*: 2006-08-24
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A randomised, double-blind, double-dummy, parallel-group, placebo-controlled study comparing correlates of brain functional activation before and after treatment with placebo, active comparator par...
    Medical condition: Major Depressive Disorder
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-022017-26 Sponsor Protocol Number: R01116 Start Date*: 2011-01-07
    Sponsor Name:Central Manchester University Hospitals Foundation Trust
    Full Title: A pilot study on the effects of an alternate-day corticosteroid regimen in children with active crohn’s disease
    Medical condition: Crohn's disease
    Disease: Version SOC Term Classification Code Term Level
    12. 10013099 Disease Crohns LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-004889-17 Sponsor Protocol Number: MAD 105516 Start Date*: 2006-05-23
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A randomized, double-blind, placebo-controlled, crossover study to evaluate the effects of morning administration of GW679769 (10mg and 30 mg) on polysomnograph sleep recordings, subjective sleep a...
    Medical condition: Primary insomnia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-004984-32 Sponsor Protocol Number: NKF100096 Start Date*: 2005-06-10
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A Randomised, Double-Blind, Double-Dummy, Parallel-Group, Placebo-Controlled, Forced Dose Titration Study Evaluating the Efficacy and Safety of GW679769 and Paroxetine in Subjects with Major Depres...
    Medical condition: Major Depressive Disorder (MDD)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SK (Completed) SE (Completed) DE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-004333-34 Sponsor Protocol Number: EORTC 55041 Start Date*: 2005-09-20
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: A randomized, multicentre, phase III study of Erlotinib versus observation in patients with no evidence of disease progression after first line, platinum-based chemotherapy for high-risk Stage I an...
    Medical condition: Histologically confirmed high-risk FIGO stage I (grade 3, or aneuploid grade 1 or 2, or clear cell), or Stages II-IV ovarian epithelial, primary peritoneal, and fallopian tube cancer.
    Disease: Version SOC Term Classification Code Term Level
    8.0 10033283 HLGT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) ES (Completed) IT (Completed) AT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-002560-28 Sponsor Protocol Number: N19PEM Start Date*: 2020-11-13
    Sponsor Name:NKI-AVL
    Full Title: PEMbrolizumab Plus Lenvatinib In Second Line And Third Line Malignant Pleural MEsotheLiomA Patients.
    Medical condition: unresectable malignant pleural mesothelioma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059518 Pleural mesothelioma malignant PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-003597-10 Sponsor Protocol Number: CRH103390 Start Date*: 2006-11-04
    Sponsor Name:GlaxoSmithKline Research & Development
    Full Title: Study CRH103390: A 12 Week Flexible Dose Study of GW876008, Placebo and Active Control (Paroxetine) in the Treatment of Social Anxiety Disorder (SocAD)
    Medical condition: Social Anxiety Disorder (SocAD)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10041242 Social anxiety disorder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2020-000236-22 Sponsor Protocol Number: Study_protocol_CODEX-P_ver2_1 Start Date*: 2020-12-16
    Sponsor Name:Chronic Obstructive Pulmonary Disease Trial Network (COP:TRIN)
    Full Title: COPD EXacerbation and Pulmonary hypertension Trial - The effect of Sildenafil treatment to patients with COPD exacerbation and pulmonary hypertension
    Medical condition: This study will investigate treatment of patients with chronic obstructive pulmonary disease (COPD), who experience frequent exacerbations (AECOPD). Only patients with a minimum of 2 moderate AECOP...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004854 10019203 Head spinning LLT
    20.1 100000004852 10033405 Pain head LLT
    20.0 100000004852 10019218 Headache NOS LLT
    20.1 100000004856 10000460 Acid dyspepsia LLT
    22.1 100000004856 10013947 Dyspepsia aggravated LLT
    20.0 100000004856 10013948 Dyspepsia and other specified disorders of function of stomach LLT
    21.1 100000004856 10019328 Heartburn-like dyspepsia LLT
    20.1 100000004856 10064536 Functional dyspepsia LLT
    23.1 100000004856 10012727 Diarrhea LLT
    20.0 100000004859 10023222 Joint pain LLT
    21.0 100000004859 10025012 Lumbo-sacral pain LLT
    21.1 100000004859 10028322 Muscle pain LLT
    20.0 100000004856 10033394 Pain epigastric LLT
    21.1 100000004866 10016046 Facial flushing LLT
    20.0 100000004853 10013614 Double vision LLT
    21.0 100000004848 10005604 Blood in urine LLT
    20.0 100000004872 10018801 Gynecomastia LLT
    20.0 100000004872 10060603 Hematospermia LLT
    20.0 100000004851 10002272 Anemia LLT
    22.1 100000004853 10034961 Photophobia aggravated LLT
    20.0 100000004871 10023139 Jaundice NOS LLT
    20.0 100000004853 10030042 Ocular hyperemia LLT
    20.1 100000004853 10051304 Retinal bleeding LLT
    20.1 100000004853 10005889 Blurry vision LLT
    20.1 100000004856 10046272 Upper abdominal pain LLT
    20.0 100000004856 10038263 Reflux oesophagitis LLT
    20.0 100000004856 10047706 Vomiting NOS LLT
    20.0 100000004867 10016558 Fever LLT
    21.1 100000004862 10024969 Lower respiratory tract infection NOS LLT
    20.0 100000004859 10048317 Myalgia aggravated LLT
    21.1 100000004859 10003990 Back pain (without radiation) LLT
    20.1 100000004852 10020922 Hypesthesia LLT
    20.0 100000004852 10027605 Migraine NOS LLT
    21.1 100000004852 10044572 Tremor limb LLT
    20.1 100000004852 10044570 Tremor finger LLT
    20.0 100000004873 10002856 Anxiety attack LLT
    20.0 100000004873 10022442 Insomnia NOS LLT
    20.0 100000004855 10011232 Coughing LLT
    20.0 100000004862 10040756 Sinusitis NOS LLT
    20.0 100000004867 10014210 Edema LLT
    20.0 100000004867 10014211 Edema (NOS) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-001341-14 Sponsor Protocol Number: BAY 59-7939 / 11527 Start Date*: 2004-11-04
    Sponsor Name:Bayer HealthCare AG
    Full Title: Controlled, Double-Blind, Randomized, Dose-ranging Study of once-daily regimen of BAY59-7939 in the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement-ODIXaHIP-OD Study
    Medical condition: Deep Venous Thrombosis prophylaxis
    Disease: Version SOC Term Classification Code Term Level
    7.0 10012108
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) SE (Completed) AT (Completed) ES (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 12 08:12:13 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA